Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Abstract

In July 2020, Eastman Kodak Company (Kodak) received a USD765 million loan from the US federal government for drug component manufacturing. Kodak's chief executive officer (CEO) was confident about the company's ability to excel in the pharmaceutical industry. However, critics cited several concerns, such as workforce availability and Kodak's lack of experience in the pharma business. The CEO believed that Kodak's expertise in advanced chemicals and manufacturing could drive the firm's success in the pharma business. Would Kodak be able to establish its mark in the US pharma industry? What challenges was Kodak likely to face?

Teaching and learning

This item is suitable for undergraduate and postgraduate courses.
Location:
Industry:
Size:
Large
Other setting(s):
2020

About

Abstract

In July 2020, Eastman Kodak Company (Kodak) received a USD765 million loan from the US federal government for drug component manufacturing. Kodak's chief executive officer (CEO) was confident about the company's ability to excel in the pharmaceutical industry. However, critics cited several concerns, such as workforce availability and Kodak's lack of experience in the pharma business. The CEO believed that Kodak's expertise in advanced chemicals and manufacturing could drive the firm's success in the pharma business. Would Kodak be able to establish its mark in the US pharma industry? What challenges was Kodak likely to face?

Teaching and learning

This item is suitable for undergraduate and postgraduate courses.

Settings

Location:
Industry:
Size:
Large
Other setting(s):
2020

Related